Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer
Status:
Completed
Trial end date:
2020-01-31
Target enrollment:
Participant gender:
Summary
This is a prospective, single-center, single-arm clinical study, to evaluate the clinical
efficacy, safety and tolerance of patients with early breast cancer receiving ddEC adjuvant
chemotherapy, accepting PEG-rhG-CSF as primary prevention of neutropenia.